Transforming the blood glucose meter into a general healthcare meter for in vitro diagnostics in mobile health

Tian Lan, Jingjing Zhang, Yi Lu

Research output: Contribution to journalReview article

Abstract

Recent advances in mobile network and smartphones have provided an enormous opportunity for transforming in vitro diagnostics (IVD) from central labs to home or other points of care (POC). A major challenge to achieving the goal is a long time and high costs associated with developing POC IVD devices in mobile Health (mHealth). Instead of developing a new POC device for every new IVD target, we and others are taking advantage of decades of research, development, engineering and continuous improvement of the blood glucose meter (BGM), including those already integrated with smartphones, and transforming the BGM into a general healthcare meter for POC IVDs of a wide range of biomarkers, therapeutic drugs and other analytical targets. In this review, we summarize methods to transduce and amplify selective binding of targets by antibodies, DNA/RNA aptamers, DNAzyme/ribozymes and protein enzymes into signals such as glucose or NADH that can be measured by commercially available BGM, making it possible to adapt many clinical assays performed in central labs, such as immunoassays, aptamer/DNAzyme assays, molecular diagnostic assays, and enzymatic activity assays onto BGM platform for quantification of non-glucose targets for a wide variety of IVDs in mHealth.

Original languageEnglish (US)
Pages (from-to)331-341
Number of pages11
JournalBiotechnology Advances
Volume34
Issue number3
DOIs
StatePublished - May 1 2016

Fingerprint

Point-of-Care Systems
Telemedicine
Glucose
Blood Glucose
Blood
Catalytic DNA
Nucleotide Aptamers
Assays
Delivery of Health Care
Smartphones
Diagnostic Reagent Kits
Catalytic RNA
Molecular Pathology
Enzyme Assays
Immunoassay
NAD
Biomarkers
RNA
Antibodies
Wireless networks

Keywords

  • Aptamer
  • Biosensors
  • Blood Glucose Meter
  • DNAzyme
  • Enzymatic activity assay
  • Immunoassay
  • In vitro diagnostics
  • Mobile health
  • Molecular diagnostics
  • Point of care

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology

Cite this

Transforming the blood glucose meter into a general healthcare meter for in vitro diagnostics in mobile health. / Lan, Tian; Zhang, Jingjing; Lu, Yi.

In: Biotechnology Advances, Vol. 34, No. 3, 01.05.2016, p. 331-341.

Research output: Contribution to journalReview article

@article{9c9bdf4443914ec2ada7b46a320c502b,
title = "Transforming the blood glucose meter into a general healthcare meter for in vitro diagnostics in mobile health",
abstract = "Recent advances in mobile network and smartphones have provided an enormous opportunity for transforming in vitro diagnostics (IVD) from central labs to home or other points of care (POC). A major challenge to achieving the goal is a long time and high costs associated with developing POC IVD devices in mobile Health (mHealth). Instead of developing a new POC device for every new IVD target, we and others are taking advantage of decades of research, development, engineering and continuous improvement of the blood glucose meter (BGM), including those already integrated with smartphones, and transforming the BGM into a general healthcare meter for POC IVDs of a wide range of biomarkers, therapeutic drugs and other analytical targets. In this review, we summarize methods to transduce and amplify selective binding of targets by antibodies, DNA/RNA aptamers, DNAzyme/ribozymes and protein enzymes into signals such as glucose or NADH that can be measured by commercially available BGM, making it possible to adapt many clinical assays performed in central labs, such as immunoassays, aptamer/DNAzyme assays, molecular diagnostic assays, and enzymatic activity assays onto BGM platform for quantification of non-glucose targets for a wide variety of IVDs in mHealth.",
keywords = "Aptamer, Biosensors, Blood Glucose Meter, DNAzyme, Enzymatic activity assay, Immunoassay, In vitro diagnostics, Mobile health, Molecular diagnostics, Point of care",
author = "Tian Lan and Jingjing Zhang and Yi Lu",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.biotechadv.2016.03.002",
language = "English (US)",
volume = "34",
pages = "331--341",
journal = "Biotechnology Advances",
issn = "0734-9750",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Transforming the blood glucose meter into a general healthcare meter for in vitro diagnostics in mobile health

AU - Lan, Tian

AU - Zhang, Jingjing

AU - Lu, Yi

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Recent advances in mobile network and smartphones have provided an enormous opportunity for transforming in vitro diagnostics (IVD) from central labs to home or other points of care (POC). A major challenge to achieving the goal is a long time and high costs associated with developing POC IVD devices in mobile Health (mHealth). Instead of developing a new POC device for every new IVD target, we and others are taking advantage of decades of research, development, engineering and continuous improvement of the blood glucose meter (BGM), including those already integrated with smartphones, and transforming the BGM into a general healthcare meter for POC IVDs of a wide range of biomarkers, therapeutic drugs and other analytical targets. In this review, we summarize methods to transduce and amplify selective binding of targets by antibodies, DNA/RNA aptamers, DNAzyme/ribozymes and protein enzymes into signals such as glucose or NADH that can be measured by commercially available BGM, making it possible to adapt many clinical assays performed in central labs, such as immunoassays, aptamer/DNAzyme assays, molecular diagnostic assays, and enzymatic activity assays onto BGM platform for quantification of non-glucose targets for a wide variety of IVDs in mHealth.

AB - Recent advances in mobile network and smartphones have provided an enormous opportunity for transforming in vitro diagnostics (IVD) from central labs to home or other points of care (POC). A major challenge to achieving the goal is a long time and high costs associated with developing POC IVD devices in mobile Health (mHealth). Instead of developing a new POC device for every new IVD target, we and others are taking advantage of decades of research, development, engineering and continuous improvement of the blood glucose meter (BGM), including those already integrated with smartphones, and transforming the BGM into a general healthcare meter for POC IVDs of a wide range of biomarkers, therapeutic drugs and other analytical targets. In this review, we summarize methods to transduce and amplify selective binding of targets by antibodies, DNA/RNA aptamers, DNAzyme/ribozymes and protein enzymes into signals such as glucose or NADH that can be measured by commercially available BGM, making it possible to adapt many clinical assays performed in central labs, such as immunoassays, aptamer/DNAzyme assays, molecular diagnostic assays, and enzymatic activity assays onto BGM platform for quantification of non-glucose targets for a wide variety of IVDs in mHealth.

KW - Aptamer

KW - Biosensors

KW - Blood Glucose Meter

KW - DNAzyme

KW - Enzymatic activity assay

KW - Immunoassay

KW - In vitro diagnostics

KW - Mobile health

KW - Molecular diagnostics

KW - Point of care

UR - http://www.scopus.com/inward/record.url?scp=84959917905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959917905&partnerID=8YFLogxK

U2 - 10.1016/j.biotechadv.2016.03.002

DO - 10.1016/j.biotechadv.2016.03.002

M3 - Review article

C2 - 26946282

AN - SCOPUS:84959917905

VL - 34

SP - 331

EP - 341

JO - Biotechnology Advances

JF - Biotechnology Advances

SN - 0734-9750

IS - 3

ER -